Xeris Biopharma Holdings, Inc. XERS Income Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $291.85M+43.7% | $203.07M+23.9% | $163.91M+48.7% | $110.25M+122% | ||
| $42.57M+15.6% | $36.83M+28.6% | $28.65M+26.6% | $22.63M+70.0% | ||
| $31.17M+21.9% | $25.56M+14.4% | $22.34M+6.6% | $20.97M-16.7% | ||
| $182.37M+11.6% | $163.48M+11.9% | $146.1M+6.1% | $137.75M+9.6% | ||
| $10.84M0.0% | $10.84M0.0% | $10.84M0.0% | $10.84M+1,871% | ||
| $266.95M+12.8% | $236.72M+13.8% | $207.92M+8.2% | $192.19M+16.7% | ||
| $24.9M+170% | -$35.33M+19.7% | -$44.01M+46.3% | -$81.94M+28.8% | ||
| 8.5%+25.9pp | -17.4%+9.5pp | -26.8%+47.5pp | -74.3%+158pp | ||
| $29.08M-4.6% | $30.49M+14.6% | $26.61M+73.6% | $15.33M+113% | ||
| $4.74M-10.9% | $5.32M+12.0% | $4.75M+84.3% | $2.58M+724% | ||
| -$24.34M-3.8% | -$23.46M-20.3% | -$19.49M— | —— | ||
| $0+100% | -$2.27M-81.6% | -$1.25M+12.3% | -$1.42M— | ||
| $554K+101% | -$54.84M+11.9% | -$62.26M+34.2% | -$94.66M+22.9% | ||
| 0.2%+27.2pp | -27%+11.0pp | -38%+47.9pp | -85.9%+162pp | ||
| $0.00+100% | -$0.38+13.6% | -$0.44+37.1% | -$0.70+54.5% | ||
| $0.00+100% | -$0.38+13.6% | -$0.44+37.1% | -$0.70+54.5% | ||
| 662.3M+13.3% | 584.6M+6.3% | 550.2M+1.5% | 542.1M+98.5% | ||
| 636M+8.8% | 584.6M+6.3% | 550.2M+1.5% | 542.1M+98.5% | ||
| $10.84M0.0% | $10.84M0.0% | $10.84M0.0% | $10.84M+1,871% | ||
| $554K+101% | -$54.84M+11.9% | -$62.26M+34.2% | -$94.65M+22.9% | ||
| $4.74M-10.9% | $5.32M+12.0% | $4.75M+84.3% | $2.58M+724% | ||
| —— | $0— | $0-100% | $1K— | ||
| -$24.34M-3.8% | -$23.46M-20.3% | -$19.49M— | —— | ||
| $291.85M+43.7% | $203.07M+23.9% | $163.91M+48.7% | $110.25M+123% | ||
| $24.9M+170% | -$35.33M+19.7% | -$44.01M+46.3% | -$81.94M+28.8% | ||
| $26.21M+177% | -$34.1M+19.8% | -$42.52M+47.2% | -$80.54M+29.2% | ||
| $26.21M+177% | -$34.1M+19.8% | -$42.52M+47.2% | -$80.54M+29.2% | ||
| 9%+25.8pp | -16.8%+9.2pp | -25.9%+47.1pp | -73.1%+156pp | ||
| $24.9M+170% | -$35.33M+19.7% | -$44.01M+46.3% | -$81.94M+28.8% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Xeris Biopharma Holdings, Inc.'s revenue?
- Xeris Biopharma Holdings, Inc. (XERS) generated $314.9M in revenue over the trailing twelve months, up 41.5% year over year.
- Is Xeris Biopharma Holdings, Inc. profitable?
- Xeris Biopharma Holdings, Inc. reported $12.0M in net income over the trailing twelve months, a 3.8% net margin.
- What are Xeris Biopharma Holdings, Inc.'s profit margins?
- Gross margin is 85.9% and operating margin is 11.4%, with a 3.8% net margin.
- What is Xeris Biopharma Holdings, Inc.'s earnings per share?
- Xeris Biopharma Holdings, Inc.'s diluted EPS over the trailing twelve months is $0.07.
- Where does Xeris Biopharma Holdings, Inc.'s income statement data come from?
- Every line is extracted from Xeris Biopharma Holdings, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
